Heterogeneity might depend on the autoantibodies (i.e., antibodies purified from the CSF or the serum of patients suffering from Rasmussen’s encephalitis, FTD, or autoimmune encephalitis, as well as antibodies isolated from the CSF of animals immunized with a GluA antigen), on the CNS regions under study, on the experimental conditions applied (the titer and the time of exposure to the autoantibodies, the animal models), and on the targeted subunit (GluA3 or GluA1 and 2). This evidence concerns the gene GRIA1 and autoimmune encephalitis.